Inhibition of P38 Mitogen-Activated Protein Kinase Exerts a Hypoglycemic Effect by Improving Β Cell Function Via Inhibition of Β Cell Apoptosis in Db/db Mice.

Xiaowei Wei,Nan Gu,Nan Feng,Xiaohui Guo,Xiaowei Ma
DOI: https://doi.org/10.1080/14756366.2018.1477138
2018-01-01
Journal of Enzyme Inhibition and Medicinal Chemistry
Abstract:The p38 mitogen-activated protein kinase (MAPK) pathway is involved in endoplasmic reticulum stress (ERS) and inflammation, which may play an important role in the pathogenesis of type 2 diabetes (T2DM). This study aimed to investigate whether p38 MAPK contributes to the pathogenesis of T2DM. 6-week-old female db/db mice were randomly assigned to Dmo and Dmi groups, and C57 mice were assigned as controls. The Dmi group was gavaged with the p38 MAPK inhibitor SB203580 for 9 weeks, and the effects on β cell dysfunction and apoptosis were investigated. db/db mice showed higher food intake, body mass, fasting glucose, and plasma insulin levels than C57 mice. After SB203580 administration, blood glucose was significantly lower. HOMA β and HOMA IR were improved. Islet mRNA expression levels of the ERS markers were lower. P38 MAPK inhibition reduced blood glucose and improved β cell function, at least in part by reducing β cell apoptosis.
What problem does this paper attempt to address?